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less often successful (95 vs. 78%, p=0.001) and more likely to be associated with a pro-
cedural MI (15 vs. 4%, p=0.005). RPB pts had a 20% in-hospital mortality vs. 3% for con-
trols (p<0.001). Event frequencies at 6 months (with Kaplan-Meier estimated rate) are
depicted below:
Conclusions: RPB is a serious complication associated with severe in-hospital and 6
month morbidity and mortality
1155-81 Radiation Exposure to Patients During Diagnostic 
Cardiac Catheterization
Kunadian Vijayalakshmi, Dee Kelly, David Williams, Mark A. de Belder, The James Cook 
University Hospital, Middlesbrough, United Kingdom
Cardiac catheterisation is a widely performed procedure. Ionising radiation during these
procedures results in an increased risk of radiation induced effects. Cardiac investiga-
tions vary in their complexity according to the information being sought. Exposure time
and radiation risks of such procedures are not fully documented. An estimation of the
effective dose (ED) can be obtained from the measurements of the dose-area product
(DAP). Published reports state an estimate of 2.5% per Sievert lifetime risk of fatal cancer
for a population between the ages of 40 and 60 years.
Aims and methods: A retrospective analysis of adult cardiac procedures was carried
out in a regional cardiothoracic unit to determine the DAP, ED and estimated risk of
malignancy. We compared 7 diagnostic groups (Table 1). Dose-area product meter (Dia-
mentor PTW, Freiberg) attached on the X-ray unit (Philips Polydiagnost C2 image intensi-
fier system) was used for the estimation of the radiation dose received by the patient
during the procedures.
Results: A total of 4,706 different procedures were studied (Table 1). Average age and
weight of the patients were 60.9 years and 79.5 kgs respectively.
Conclusions: Cardiac angiographic procedures other than a straightforward investiga-
tion of native coronaries ± left venticulography are associated with significantly high radi-
ation doses. Patient exposure is particularly high in those undergoing graft studies
(p=0.0001).
1155-82 Reduced Fluoroscopy Time and Cine Sequences With 
Digital Flat Panel Technology
Christopher L. Sarnoski, Peter J. Higgins, Thomas J. Ryan, Jr., Mirle A. Kellet, Jr., 
William A. Dietz, Priya Gopinath, Maine Medical Center, Portland, ME, G.E. Medical 
Systems, Waukesha, WI
Background: Digital Flat Panel Systems (DFPS) (GE Innova 2000TM, Waukesha, WI)
have been shown to provide real time cardiac images with improved image quality at
lower radiation doses in comparison to conventional Image Intensifier Systems (IIS).
There is no data showing that the use of this technology impacts resources and patient
care. We have hypothesized performing percutaneous cardiac intervention(PCI) with
DFPS will lead to shorter case time, fluoroscopy time, number of cine runs, and less con-
trast.
Methods: All PCI’s performed using DFPS and IIS during the year 2002 by four high vol-
ume operators were reviewed. Single vessel, single stent procedures without diagnostic
angiography were selected. Patients were matched for body surface area (BSA), artery,
guide size, stent length and diameter. A total of 133 patients were analyzed(85 IIS cases,
48 DFPS cases).
Results: Table 1.
Conclusion: On average, the operator spent 15% less time (p<0.05) using fluoroscopy
and took 12% fewer cines (p<0.05) using DFPS. While there is a trend towards less con-
trast use and shorter case length times with DFPS, the mean values did not reach statis-
tical significance. Using DFPS leads to less fluoroscopy time and cine runs which may
ultimately decrease the amount of radiation exposure to both staff and patients. A more
complex patient population(larger BSA) or intervention(multivessel) may yield even
greater benefits.
1155-83 A Pooled Analysis of Sirolimus and Paclitaxel-Eluting 
Stent Trials
Mohan Babapulle, Mark J. Eisenberg, Jewish General Hospital, Montreal, PQ, Canada
Background: Several clinical trials have examined the efficacy of drug-eluting stents
(DES) at reducing restenosis rates following percutaneous coronary intervention.
Although DES appear to decrease restenosis rates, a pooled analysis has not been pub-
lished that examines treatment effect.
Methods: We performed a pooled analysis of 4 clinical trials involving over 1,700
patients examining Sirolimus-eluting stents, and 5 trials involving over 1,900 patients
examining Paclitaxel-eluting stents. The outcomes of interest were binary restenosis
rates and major adverse cardiac event rates (MACE) (composite of death, myocardial inf-
arction and target lesion revascularization).
Results: In each trial, the treatment group showed lower binary restenosis rates and
lower MACE rates compared to the control group (Table 1). In-stent or in-segment binary
restenosis rates were reduced by 89% (95% Confidence Interval (CI) 84-92%) in Siroli-
mus-eluting stent trials and by 67% (95% CI 55-76%) in Paclitaxel-eluting stent trials.
MACE rates were reduced by 72% (95% CI 63-79%) in Sirolimus trials and by 40% (95%
CI 21-54%) in Paclitaxel trials. For all trials combined, DES were associated with an 81%
reduction in binary restenosis rates (95% CI 76-85%), and a 59% reduction in MACE
rates (95% CI 51-76%). 
Conclusions: Sirolimus and Paclitaxel-eluting stents substantially reduce restenosis and
MACE rates over the short and mid-term.
Table 1. Pooled Analysis of Sirolimus and Paclitaxel Eluting Stent Trials 








Death 10 (4.6) 16 (29) 7.20 <0.00
1
Death/MI 30 (14) 20 (36) 3.06 <0.00
1
Death/MI/Angina 55 (25) 21 (38) 1.71 0.037
Death/MI/Angina/
Revascularization
64 (23) 23 (42) 1.62 0.047
Table 1
Screening time, DAP, ED and estimated risk of malignancy for diagnostic 













Estimated risk of 
malignanacy (%)




248 ± 325 15.7 ± 
13
3.4 0.008%




200 ± 243 16.8 ± 
9
3.7 0.009%




524 ± 387 28.8 ± 
15
6.3 0.015%
Group 4 (Left ventriculography 
+ aortography)
11 437 ± 470 26.5 ± 
11
5.8 0.014%
Group 5 (LHC + aortography) 16
8
416 ± 424 26.5 ± 
14
5.7 0.014%
Group 6 (LHC + graft study) 18
9
700 ± 518 31.3 ± 
14
6.8 0.0175
Group 7 (LHC + aortography + 
graft study)






Digital Flat Panel System
(GE Innova 2000)
p Value
Fluoroscopy Time (minutes) 10.6 9.0 0.016
Number of Cine Runs 21.0 18.5 0.002
Total Case Time(minutes) 34.0 32.0 0.465
Volume of Contrast (cc) 250.0 234.0 0.152
Trial Coating Binary Restenosis 6-8 
months
MACE 6-12 months
Treatment Control Treatment Control 
RAVEL Sirolimu
s





1/43 23/43 2/50 9/50
SIRIUS Sirolimu
s





9/152 67/156 14/175 40/177
Sirolimus-Pooled 
(%)
41/663 (6.2) 249/670 (37.2) 74/878 (8.4) 214/870 (24.6)
Taxus I Paclitaxe
l
0/30 3/29 0/31 3/30
Taxus II Paclitaxe
l
19/255 67/263 27/266 57/270
ASPECT Paclitaxe
l
8/100 15/55 10/117 3/59
DELIVER Paclitaxe
l
38/228 48/214 53/517 68/512
ELUTES Paclitaxe
l
4/138 7/35 15/152 7/38
Paclitaxel-Pooled 
(%)
69/751 (9.2) 140/596 (23.5) 105/1083 
(9.7)
138/909 (15.2)
Total (%) 110/1,414 
(7.8)
389/1,266 
(30.7)
179/1,961 
(9.1)
352/1,779 
(19.8)
